How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Antidiabetic Sulphonylureas Market
- By Drug Generation: First-generation sulphonylureas, Second-generation sulphonylureas, Third-generation sulphonylureas
- By Molecule Type: Glyburide (Glibenclamide), Glipizide, Glimepiride, Chlorpropamide, Tolbutamide
- By Route of Administration: Oral tablets, Oral extended-release tablets
- By End User: Hospitals, Clinics, Retail Pharmacies, Online Pharmacies
- By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - First-generation sulphonylureas leads By Drug Generation at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 287 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.173 →
- 12 Company Profiles 15 players: SWOT & benchmarking p.181 →
Full report · locked preview
Everything inside the Antidiabetic Sulphonylureas Market report
A complete, evidence-based study - 12 chapters and 120 sections covering market size, segmentation across 5 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Drug Generation 3
Molecule Type 5
Route of Administration 2
End User 4
Distribution Channel 3
Companies profiled
Sanofi
Eli Lilly and Company
Novo Nordisk
Boehringer Ingelheim
Mylan (Viatris)
Sun Pharmaceutical Industries
Cipla
Dr. Reddy's Laboratories
Zhejiang Huahai Pharmaceutical
Aurobindo Pharma
Lupin Limited
Torrent Pharmaceuticals
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Sanofi
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Eli Lilly and Company
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Novo Nordisk
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Boehringer Ingelheim
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Mylan (Viatris)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Sun Pharmaceutical Industries
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Cipla
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Dr. Reddy's Laboratories
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Zhejiang Huahai Pharmaceutical
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Aurobindo Pharma
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Lupin Limited
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Torrent Pharmaceuticals
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Cadila Healthcare (Zydus)
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Teva Pharmaceutical Industries
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Sandoz (Novartis)
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$7,172M by 2033 · 3.4% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- First-generation sulphonylureas56.0
- Second-generation sulphonylureas21.6
- Third-generation sulphonylureas22.4
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,808M → $2,262M · 2.8%
Europe$1,260M → $1,730M · 4.0%
Asia Pacific$1,150M → $1,348M · 2.0%
Latin America$712.2M → $832.7M · 2.0%
Middle East and Africa$547.8M → $769.4M · 4.3%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →3.382026
3.402027
3.392028
3.412029
3.432030
3.432031
3.442032
3.462033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Sanofi23.0
- Eli Lilly and Company21.0
- Novo Nordisk9.6
- Boehringer Ingelheim10.0
- Mylan (Viatris)4.6
- Sun Pharmaceutical Industries3.7
- Others28.1
Segment contribution to growth (%)
Fig. 18 · p.39 →Drug Generation19.2%
Molecule Type26.0%
Route of Administration23.8%
End User11.0%
Distribution Channel20.0%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America32.6
- Europe24.9
- Asia Pacific19.4
- Latin America12.0
- Middle East and Africa11.1
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Sanofi | 84 | 87 | 90 | 84 | 90 | 97 | 89 |
| Eli Lilly and Company | 78 | 81 | 74 | 86 | 75 | 71 | 78 |
| Novo Nordisk | 81 | 75 | 78 | 86 | 75 | 82 | 80 |
| Boehringer Ingelheim | 68 | 70 | 59 | 61 | 70 | 58 | 64 |
| Mylan (Viatris) | 53 | 64 | 66 | 68 | 68 | 67 | 64 |
| Sun Pharmaceutical Industries | 46 | 55 | 68 | 60 | 52 | 55 | 56 |
| Cipla | 41 | 44 | 59 | 57 | 56 | 41 | 50 |
| Dr. Reddy's Laboratories | 35 | 55 | 37 | 50 | 43 | 39 | 43 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Sanofi
- Eli Lilly and Company
- Novo Nordisk
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Sanofi | ◐ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Eli Lilly and Company | ✓ | ◐ | ◐ | ✓ | ✓ | − |
| Novo Nordisk | ✓ | ✓ | ◐ | ◐ | ◐ | ◐ |
| Boehringer Ingelheim | ✓ | ✓ | − | ◐ | ◐ | ◐ |
| Mylan (Viatris) | ◐ | ◐ | − | ◐ | − | ✓ |
| Sun Pharmaceutical Industries | − | ◐ | − | ◐ | ◐ | − |
| Cipla | − | − | ◐ | − | − | − |
| Dr. Reddy's Laboratories | − | − | − | ◐ | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Sanofi89
2Novo Nordisk80
3Eli Lilly and Company78
4Boehringer Ingelheim64
5Mylan (Viatris)64
6Sun Pharmaceutical Industries56
7Cipla50
8Dr. Reddy's Laboratories43
Competitive tiers
§8.4 · p.172 →Leader3
Set the pace on share, breadth and innovation.
SanofiEli Lilly and CompanyNovo Nordisk
Contender2
Focused players with pockets of strength.
Boehringer IngelheimMylan (Viatris)
Niche3
Specialists in a single segment or region.
Sun Pharmaceutical IndustriesCiplaDr. Reddy's Laboratories
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Drug Generation in North America, then scale across Antidiabetic Sulphonylureas Market — a $271M beachhead inside a $4.60B market.
Beachhead (SOM)$271Mobtainable near-term
Serviceable (SAM)$1.82Breachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale5 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion91 fit
First-generation sulphonylureas
Best fit — highest urgency & budget in Drug Generation.
Economic buyer75 fit
Second-generation sulphonylureas
Strong fit — clear ROI and a fast path to value.
End user70 fit
Third-generation sulphonylureas
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Drug Generation in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Molecule Type & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Route of Administration
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales43%
Partner / channel27%
Digital / self-serve21%
Marketplaces8%
Positioning & messaging
§GTM 2 · p.194 →For Drug Generation leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Antidiabetic Sulphonylureas Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified44%
Sales qualified23%
Evaluation12%
Closed-won5%
$21.8KCAC
$118KLTV
5.4:1LTV : CAC
< 3 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Antidiabetic Sulphonylureas Market is a durable-growth opportunity — $4.24B by 2033, compounding at 7.8%.
TAM · 2025$2.33Btoday
TAM · 2033$4.24Bforecast
CAGR7.8%2027–2033
Cumulative$28.9Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$4.24BTotal addressable market
SAM$1.63BServiceable available market
SOM$329MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →7.8% CAGR
Demand compounds through 2033, outpacing GDP across Drug Generation.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Drug Generation moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$4.24BLarge & growingTAM by 2033 at 7.8% CAGR
$1.63BServiceable nowreachable with today’s model
$329MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$3.31BBear5.0% CAGR
$4.24BBase7.8% CAGR
$5.43BBull10.2% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Molecule Type optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Antidiabetic Sulphonylureas Market — a $5.37B market by 2033. Plan: grow share from 10.3% to 17.9%.
Market size · 2033$5.37Btotal addressable
Market CAGR6.2%2027–2033
Target share17.9%from 10.3% today
Revenue ambition$962Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 10.3% | 17.9% | At risk |
| Revenue | $551M | $962M | Ahead |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | On track |
| Gross margin | 31.7% | 42.0% | On track |
| Customer retention | 91.7% | 95.7% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Drug Generation
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Molecule Type capability
A defensible second engine — invest in Molecule Type to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Drug Generation share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Molecule Type
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $124M capacity & capability investment
- Greenlight bolt-on M&A in Molecule Type
- Authorise North America expansion plan
- Fund R&D program for Drug Generation leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAt risk
- Competitive share lossBehind
- Input-cost & supply riskBehind
- Regulatory / policy changeAt risk
- Execution & talentAhead
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Antidiabetic Sulphonylureas Market conversation — a $10.3B market you can size, segment and defend in minutes.
Market size · 2033$10.3Btotal opportunity
Growth8.1%CAGR to 2033
Addressable buyers1,168+accounts in scope
Typical ROI7×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Drug Generation
Goal Grow share in Drug Generation
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →7×return on cost, year one
< 3 mopayback period
$49K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
SanofiEli Lilly and CompanyNovo NordiskBoehringer IngelheimMylan (Viatris)Sun Pharmaceutical IndustriesCiplaDr. Reddy's Laboratories+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Antidiabetic Sulphonylureas Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Antidiabetic Sulphonylureas Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Akabane Vaccines Market
Market size, share, segmentation and regional forecast.
$3.0B market · 2025 base year
View reportVeterinary Anthrax Vaccines Market
Market size, share, segmentation and regional forecast.
$486M market · 2025 base year
View reportMedical Intravenous Infusion Pump Market
Market size, share, segmentation and regional forecast.
$3.5B market · 2025 base year
View reportEtoposide Market
Market size, share, segmentation and regional forecast.
$1.7B market · 2025 base year
View reportEnoxolone Market
Market size, share, segmentation and regional forecast.
$2.3B market · 2025 base year
View reportRaubasine Market
Market size, share, segmentation and regional forecast.
$3.8B market · 2025 base year
View reportAgrobacterium tumefaciens Competent Cells Market
Market size, share, segmentation and regional forecast.
$4.6B market · 2025 base year
View reportMethyl Salicylate Patches Market
Market size, share, segmentation and regional forecast.
$5.5B market · 2025 base year
View reportClotting Factor Market
Market size, share, segmentation and regional forecast.
$5.1B market · 2025 base year
View reportDiclofenac Patches Market
Market size, share, segmentation and regional forecast.
$1.5B market · 2025 base year
View reportDehydrated Culture Media Market
Market size, share, segmentation and regional forecast.
$552M market · 2025 base year
View reportDiphtheria Toxoid Market
Market size, share, segmentation and regional forecast.
$1.8B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.